🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Drugmaker Endo strikes $63 million opioid settlement with Texas

Published 12/23/2021, 02:16 PM
Updated 12/23/2021, 04:56 PM
© Reuters. FILE PHOTO: Texas Attorney General Ken Paxton speaks to anti-abortion supporters outside the U.S. Supreme Court following arguments over a challenge to a Texas law that bans abortion after six weeks in Washington, U.S., November 1, 2021. REUTERS/Evelyn Ho
CAH
-
MCK
-
COR
-
JNJ
-
ENDPQ
-

By Nate Raymond

(Reuters) - Endo International (NASDAQ:ENDP) Plc has agreed to pay $63 million to resolve claims by the state of Texas and local governments that the drugmaker helped fuel the U.S. opioid epidemic, the state's attorney general said on Thursday.

The deal announced by Texas Attorney General Ken Paxton marked the latest in a series of settlements that Endo has struck in recent months with state and local governments to resolve similar cases.

More than 3,400 lawsuits largely by state and local governments have been filed nationally accusing the Dublin-based company of contributing to the drug abuse crisis by deceptively marketing pain medications including Opana ER, which it no longer sells.

"This settlement is a necessary step in the right direction, and we will continue to fight to heal our state from this devastating crisis," Paxton said in a statement.

Endo did not admit wrongdoing. It said its goal remains to achieve a global opioid settlement but that it is also exploring "strategic alternatives." Texas' settlement includes clauses for a potential Endo bankruptcy.

Thousands of lawsuits have been filed seeking to hold drugmakers, drug distributors and pharmacy chains responsible for a drug abuse crisis the U.S. government says has led to hundreds of thousands of overdose deaths over two decades.

Drug distributors McKesson Corp (NYSE:MCK), AmerisourceBergen (NYSE:ABC) Corp and Cardinal Health Inc (NYSE:CAH) and the drugmaker Johnson & Johnson (NYSE:JNJ) are pushing to finalize proposed settlements of up to $26 billion to resolve the cases against them.

© Reuters. FILE PHOTO: Texas Attorney General Ken Paxton speaks to anti-abortion supporters outside the U.S. Supreme Court following arguments over a challenge to a Texas law that bans abortion after six weeks in Washington, U.S., November 1, 2021. REUTERS/Evelyn Hockstein

Endo is not part of the proposed $26 billion deal, but previously agreed to settle lawsuits by states or counties in Alabama, Louisiana, New York, Ohio, Oklahoma and Tennessee for more than $136 million.

In November, a California judge following a trial found Endo and three other drugmakers not liable in a lawsuit by several large counties that accused them of fueling the opioid epidemic, saying they failed to prove their $50 billion case.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.